Novartis
-
Novartis Drug Kisqali Boosts Survival Rate Of Young Breast Cancer Patients
-
World's Most Expensive Gene Therapy Zolgensma Treats Rare Genetic Disease In Infants
-
FDA Gives Thumbs Up To Multiple Sclerosis Drug From Novartis
-
First Migraine Drug In 2 Decades Can Cut Monthly Migraine Days In Half
-
Novartis CAR-T Cancer Therapy For Leukemia Gets Landmark Recommendation From FDA Panel
-
FDA Approves Rydapt For Treatment Of Acute Myeloid Leukemia In Adult Patients
-
Novartis Heart Drug Serelaxin Fails In Last Stage Clinical Trial
-
FDA Approves Novartis Kisqali As Metastatic Breast Cancer Treatment
-
Gleevec Can Keep Leukemia Patients Alive For More Than 10 years, But How Much Does It Cost?
-
Google's Smart Autofocusing Contact Lens Delayed: Tests Pushed Back Beyond 2016
-
Midostaurin In AML Improves Survival In Newly Diagnosed AML Patients
-
Novartis CART Lymphoma Therapy CTL019 Shows Positive Results In Clinical Study
Most Popular
